Vaxcyte has advanced to the Phase II trial’s second and final stage (Stage 2) assessing its 31-valent pneumococcal conjugate ...
The European Medicines Agency (EMA) has recommended granting marketing authorization for the pneumococcal vaccine Capvaxive ...
Drug major Merck & Co. (MRK) announced Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use or ...
Merck Receives Positive EU CHMP Opinion for CAPVAXIVEâ„¢ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal ...